Regeneron Pharmaceuticals (REGN) Construction in Progress (2016 - 2017)
Regeneron Pharmaceuticals (REGN) has disclosed Construction in Progress for 5 consecutive years, with $408.9 million as the latest value for Q4 2017.
- For Q4 2017, Construction in Progress rose 28.2% year-over-year to $408.9 million; the TTM value through Dec 2017 reached $408.9 million, up 28.2%, while the annual FY2017 figure was $408.9 million, 28.2% up from the prior year.
- Construction in Progress hit $408.9 million in Q4 2017 for Regeneron Pharmaceuticals, up from $318.9 million in the prior quarter.
- Across five years, Construction in Progress topped out at $579.8 million in Q4 2015 and bottomed at $142.4 million in Q4 2013.
- Average Construction in Progress over 5 years is $384.4 million, with a median of $408.9 million recorded in 2017.
- Year-over-year, Construction in Progress surged 231.69% in 2014 and then tumbled 45.0% in 2016.
- Regeneron Pharmaceuticals' Construction in Progress stood at $142.4 million in 2013, then soared by 231.69% to $472.2 million in 2014, then increased by 22.79% to $579.8 million in 2015, then crashed by 45.0% to $318.9 million in 2016, then rose by 28.2% to $408.9 million in 2017.
- According to Business Quant data, Construction in Progress over the past three periods came in at $408.9 million, $318.9 million, and $579.8 million for Q4 2017, Q4 2016, and Q4 2015 respectively.